目的 探究新辅助腹腔内联合全身化疗（NIPS）联合信迪利单抗在胃癌腹膜转移转化治疗中的有效性和安全性。方法 选取2021年6月—2024年6月收治的胃癌腹膜转移患者82例,根据治疗方法不同分为对照组和观察组,每组各41例。对照组采用NIPS治疗,观察组采用NIPS联合信迪利单抗治疗。对比两组临床疗效、肿瘤标志物糖类抗原（CA）125、CA19-9与癌胚抗原（CEA）和细胞因子血管内皮生长因子（VEGF）水平、随访6个月期间生存情况和毒副反应。结果 观察组的临床有效率为70.73%（29/41）,高于对照组的48.78%（20/41）,差异有统计学意义（P<0.05）。治疗前,两组间CA125、CA19-9、CEA以及VEGF水平差异均无统计学意义;治疗3个周期后,两组上述指标均较治疗前降低,且观察组水平均低于对照组,差异有统计学意义（均P<0.05）。6个月随访期间,相比于对照组41.46%（17/41）的生存率,观察组为65.85%（27/41）,明显更高（P<0.05）;两组毒副反应差异无统计学意义（P>0.05）。结论 NIPS联合信迪利单抗在胃癌腹膜转移转化治疗中显示出较高的有效性和良好的安全性,为胃癌腹膜转移患者的治疗提供了新的策略选择。

Objective To investigate the efficacy and safety of neoadjuvant intraperitoneal and systemic chemotherapy （NIPS） combined with sintilimab in the treatment of peritoneal metastasis of gastric cancer. Methods A total of 82 patients with gastric cancer peritoneal metastasis admitted from June 2021 to June 2024 were selected and divided into a control group and an observation group according to treatment methods, with 41 cases in each group. The control group was treated with NIPS therapy, while the observation group was treated with NIPS combined with sintilimab. Clinical efficacy, tumor markers carbohydrate antigen （CA） 125, CA19-9, and carcinoembryonic antigen （CEA）, cytokine levels vascular endothelial growth factor （VEGF）, 6-month survival, and toxic side effects were compared between the two groups. Results The clinical effective rate of the observation group （70.73%, 29/41） was higher than that of the control group （48.78%, 20/41） （P<0.05）. The levels of CA125, CA19-9, CEA, and VEGF were not different between the two groups before treatment; the levels were reduced after 3 months of treatment, and lower in the observation group than in the control group （P<0.05）. During the 6-month follow-up period, compared to the control group （41.46%, 17/41）, the observation group had a higher rate of survival （65.85%, 27/41） （P<0.05）. There was no statistically significant difference in toxic side effects between the two groups （P>0.05）. Conclusion The combination of NIPS and sintilimab has shown high efficacy and good safety in the treatment of gastric cancer peritoneal metastasis, providing a new choice for the treatment of patients with gastric cancer peritoneal metastasis.